Sutro Biopharma (STRO) — Cash Flow Quality Index
Sutro Biopharma (STRO) has a Cash Flow Quality Index of 0.45x as of December 2023. Operating cash flow of $14.07 Million is below net income of $31.07 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Sutro Biopharma strategic investment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sutro Biopharma Cash Flow Quality Index (2016–2016)
Historical Cash Flow Quality Index for Sutro Biopharma across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible equity quality of Sutro Biopharma to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Sutro Biopharma (2016–2016)
Year-by-year earnings quality comparison for Sutro Biopharma. For live market cap and the full company financial profile, see STRO company net worth.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2016 | -7.73x | $-13.15 Million | $1.70 Million | — |